ONCY Stock Overview
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Oncolytics Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.06 |
| 52 Week High | CA$3.39 |
| 52 Week Low | CA$0.88 |
| Beta | 1.46 |
| 1 Month Change | 2.91% |
| 3 Month Change | -15.20% |
| 1 Year Change | -16.54% |
| 3 Year Change | -65.13% |
| 5 Year Change | -44.79% |
| Change since IPO | -97.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| ONCY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.9% | 1.0% | 1.2% |
| 1Y | -16.5% | 0.7% | 24.9% |
Return vs Industry: ONCY underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: ONCY underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| ONCY volatility | |
|---|---|
| ONCY Average Weekly Movement | 11.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ONCY has not had significant price volatility in the past 3 months.
Volatility Over Time: ONCY's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 29 | Matt Coffey | www.oncolyticsbiotech.com |
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG.
Oncolytics Biotech Inc. Fundamentals Summary
| ONCY fundamental statistics | |
|---|---|
| Market cap | US$78.72m |
| Earnings (TTM) | -US$20.26m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.0x
P/E RatioIs ONCY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONCY income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$27.75m |
| Earnings | -CA$27.75m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.37 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ONCY perform over the long term?
See historical performance and comparison